Related Experiment Videos
Meningitis and epiglottitis: a new immunisation against haemophilus influenzae type b infections
Insights
Systemic Haemophilus influenzae type b (Hib) infections affect 1 in 600 children before age five, often causing meningitis. A new Hib conjugate vaccine (HbO-C) shows promise for preventing these infections through routine UK immunisation.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Systemic Haemophilus influenzae type b (Hib) disease poses a significant risk to children, with a cumulative incidence of 1:600 before age five in the Oxford region.
- Meningitis is a common complication, affecting 71% of Hib-infected children.
- Increasing antimicrobial resistance and potential incidence rise necessitate primary prevention strategies like immunisation.
Purpose of the Study:
- To evaluate the safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine (HbO-C).
- To assess the feasibility of introducing a routine immunisation programme for Hib in the UK.
Main Methods:
- A safety and immunogenicity study was conducted.
- The study focused on the Haemophilus influenzae type b conjugate vaccine (HbO-C).
Main Results:
- The study demonstrated the safety and immunogenicity of the HbO-C vaccine.
- This represents a crucial first step towards potential widespread use.
Conclusions:
- The HbO-C vaccine is a viable option for the primary prevention of Haemophilus influenzae type b disease.
- Routine immunisation could significantly reduce the incidence of Hib infections and associated complications in children.
Abstract:
Since 1985 the number of cases of systemic haemophilus influenzae type b (Hib) disease in children in the Oxford region has been recorded. This study shows that a cumulative incidence of children suffering systematic Hib infections before their fifth birthday is 1:600, 71 per cent of sufferers having meningitis. Because the incidence of haemophilus infections may be increasing in the UK and there is increasing resistance of the organism to antimicrobial therapy, the need for primary prevention through immunisation is becoming increasingly attractive. We have therefore undertaken a safety and immunogenicity study of a haemophilus influenzae type b conjugate vaccine (HbO-C) as a first step towards introducing a routine immunisation programme for the UK.